In one paragraphArticle in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Shu-Yu LinInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan.ORCID 0009-0001-4165-7602 Wen-Chieh HuangInstitute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 350401, Taiwan.ORCID 0000-0001-9599-7613 Shwu-Chen TsayDepartment of Chemistry and Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300044, Taiwan.ORCID 0000-0003-0585-3419 Johan NeytsRega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.ORCID 0000-0002-0033-7514 Pieter LeyssenRega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
Chun-Cheng LinDepartment of Chemistry and Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300044, Taiwan.ORCID 0000-0002-2323-0920 Kuo Chu HwangDepartment of Chemistry and Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300044, Taiwan.ORCID 0000-0003-1814-9869 Jia-Cherng HorngDepartment of Chemistry and Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300044, Taiwan.ORCID 0000-0002-9936-5338 Jih Ru HwuDepartment of Chemistry and Frontier Research Center on Fundamental & Applied Sciences of Matters, National Tsing Hua University, Hsinchu 300044, Taiwan.ORCID 0000-0002-9225-8484 Funding
National Health Research Institutes, Taiwan BP-114-PP-04National Health Research Institutes, Taiwan BP-114-SP-02National Science and Technology Council, Taiwan 112-2113-M-007-001National Science and Technology Council, Taiwan 14-2113-M-400-002
6 · The paper itselfAbstract
On the basis of a "chemo-combination strategy", (6-chloro)coumarin was incorporated to purines and pyrimidines, as well as their corresponding nucleosides, with a -SCH
Indexed as
Antiviral AgentsCoumarinsHepacivirusNucleosidesCell Line, TumorHumansMolecular StructurePurinesStructure-Activity RelationshipVirus ReplicationAntiviral AgentsCoumarinsNucleosidesPurinescoumarinhepatitis C virusmercaptopurinenucleosidesstructure–activity relationship
Identifiers
PMID40333753
PMCPMC12029179
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390